Key statistics
On Tuesday, ELEVAI Labs Inc (ELAB:NAQ) closed at 0.1001, 28.17% above the 52 week low of 0.0781 set on Oct 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.10 |
---|---|
High | 0.1138 |
Low | 0.099 |
Bid | 0.0975 |
Offer | 0.098 |
Previous close | 0.1051 |
Average volume | 70.99m |
---|---|
Shares outstanding | 22.10m |
Free float | 5.97m |
P/E (TTM) | -- |
Market cap | 2.21m USD |
EPS (TTM) | -0.2698 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
- REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
- Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
- Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device
- Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
- Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
- Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
- Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
- Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
- Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications
More ▼